Prognostic impact and immunotherapeutic implications of NETosis-related prognostic model in clear cell renal cell carcinoma
Background The ramifications of necroptosis on the prognostication of clear cell renal cell carcinoma (ccRCC) remain inadequately expounded. Methods A prognostic model delineating the facets of necroptosis in ccRCC was constructed, employing a compendium of algorithms. External validation was effect...
Gespeichert in:
Veröffentlicht in: | Journal of cancer research and clinical oncology 2024-05, Vol.150 (5), p.278-278, Article 278 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 278 |
---|---|
container_issue | 5 |
container_start_page | 278 |
container_title | Journal of cancer research and clinical oncology |
container_volume | 150 |
creator | Mao, Xingjun Huang, Wen Xue, Qing Zhang, Xiaolei |
description | Background
The ramifications of necroptosis on the prognostication of clear cell renal cell carcinoma (ccRCC) remain inadequately expounded.
Methods
A prognostic model delineating the facets of necroptosis in ccRCC was constructed, employing a compendium of algorithms. External validation was effectuated using the E-MTAB-1980 dataset. The exploration of immune infiltration scores was undertaken through the exploitation of multiple algorithms. Single-cell RNA sequencing data were procured from the GSE171306 dataset. Real-time quantitative PCR (RT-qPCR) was engaged to scrutinize the differential expression of SLC25A37 across cancer and paracancer tissues, as well as diverse cell lines. Assessments of proliferative and metastatic alterations in 769-P and 786-O cells were accomplished through Cell Counting Kit-8 (CCK8) and wound healing assays.
Results
The necroptosis-related signature (NRS) emerges as a discerning metric, delineating patients’ immune attributes, tumor mutation burden, immunotherapy response, and drug susceptibility. Single-cell RNA sequencing analysis unveils the marked enrichment of SLC25A37 in tumor cells. Concurrently, RT-qPCR discloses the overexpression of SLC25A37 in both ccRCC tissues and cell lines. SLC25A37 knockdown mitigates the proliferative and metastatic propensities of 769-P and 786-O cells, as evidenced by CCK8 and wound healing assays.
Conclusion
The NRS assumes a pivotal role in ascertaining the prognosis, tumor mutation burden, immunotherapy response, drug susceptibility, and immune cell infiltration features of ccRCC patients. SLC25A37 emerges as a putative player in immunosuppressive microenvironments, thereby providing a prospective avenue for the design of innovative immunotherapeutic targets for ccRCC. |
doi_str_mv | 10.1007/s00432-024-05761-y |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11129999</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3060564808</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-dc463a857ecf83871ba82e22b4c6ec47940b9abc4d28504016fa43a5d19b2ae3</originalsourceid><addsrcrecordid>eNp9kUtv1TAQhSNERUvhD7BAkdh0Exg_8lohVLWAVFEWd29NnMmtK8cOdlLpij-PL7n0waLeeOTzzRmPTpa9Y_CRAdSfIoAUvAAuCyjrihW7F9kJ2z8xIcqXj-rj7HWMtwCsLmv-KjsWTQNJhJPs98_gt87H2ejcjBPqOUfXp3JcnJ9vKOBEy0G0RuNsvIu5H_IfFxsfTSwCWZypz6cHn9H3ZHPjcm0JQ67J2jyQQ7uWGoM2zo_4Jjsa0EZ6e7hPs83lxeb8W3F1_fX7-ZerQouymotey0pgU9akh0Y0Neuw4cR5J3VFWtathK7FTsueNyVIYNWAUmDZs7bjSOI0-7zaTks3Uq_JzQGtmoIZMeyUR6OeKs7cqK2_U4wx3qaTHM4ODsH_WijOajRxvws68ktUAiqoZcslJPTDf-itX0LafaXKSjbQJIqvlA4-xkDD_W8YqH22as1WpWzV32zVLjW9f7zHfcu_MBMgViAmyW0pPMx-xvYPn7OzAA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3060564808</pqid></control><display><type>article</type><title>Prognostic impact and immunotherapeutic implications of NETosis-related prognostic model in clear cell renal cell carcinoma</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Springer Nature OA/Free Journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>Mao, Xingjun ; Huang, Wen ; Xue, Qing ; Zhang, Xiaolei</creator><creatorcontrib>Mao, Xingjun ; Huang, Wen ; Xue, Qing ; Zhang, Xiaolei</creatorcontrib><description>Background
The ramifications of necroptosis on the prognostication of clear cell renal cell carcinoma (ccRCC) remain inadequately expounded.
Methods
A prognostic model delineating the facets of necroptosis in ccRCC was constructed, employing a compendium of algorithms. External validation was effectuated using the E-MTAB-1980 dataset. The exploration of immune infiltration scores was undertaken through the exploitation of multiple algorithms. Single-cell RNA sequencing data were procured from the GSE171306 dataset. Real-time quantitative PCR (RT-qPCR) was engaged to scrutinize the differential expression of SLC25A37 across cancer and paracancer tissues, as well as diverse cell lines. Assessments of proliferative and metastatic alterations in 769-P and 786-O cells were accomplished through Cell Counting Kit-8 (CCK8) and wound healing assays.
Results
The necroptosis-related signature (NRS) emerges as a discerning metric, delineating patients’ immune attributes, tumor mutation burden, immunotherapy response, and drug susceptibility. Single-cell RNA sequencing analysis unveils the marked enrichment of SLC25A37 in tumor cells. Concurrently, RT-qPCR discloses the overexpression of SLC25A37 in both ccRCC tissues and cell lines. SLC25A37 knockdown mitigates the proliferative and metastatic propensities of 769-P and 786-O cells, as evidenced by CCK8 and wound healing assays.
Conclusion
The NRS assumes a pivotal role in ascertaining the prognosis, tumor mutation burden, immunotherapy response, drug susceptibility, and immune cell infiltration features of ccRCC patients. SLC25A37 emerges as a putative player in immunosuppressive microenvironments, thereby providing a prospective avenue for the design of innovative immunotherapeutic targets for ccRCC.</description><identifier>ISSN: 1432-1335</identifier><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-024-05761-y</identifier><identifier>PMID: 38801430</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Algorithms ; Biomarkers, Tumor - genetics ; Cancer Research ; Carcinoma, Renal Cell - genetics ; Carcinoma, Renal Cell - immunology ; Carcinoma, Renal Cell - pathology ; Carcinoma, Renal Cell - therapy ; Cell Line, Tumor ; Cell Proliferation ; Clear cell-type renal cell carcinoma ; Gene Expression Regulation, Neoplastic ; Hematology ; Humans ; Immunotherapy ; Immunotherapy - methods ; Infiltration ; Internal Medicine ; Kidney cancer ; Kidney Neoplasms - genetics ; Kidney Neoplasms - immunology ; Kidney Neoplasms - pathology ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Microenvironments ; Mutation ; Necroptosis ; Oncology ; Prognosis ; Sequence analysis ; Tumor cells ; Tumor Microenvironment - immunology ; Tumors ; Wound healing</subject><ispartof>Journal of cancer research and clinical oncology, 2024-05, Vol.150 (5), p.278-278, Article 278</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c356t-dc463a857ecf83871ba82e22b4c6ec47940b9abc4d28504016fa43a5d19b2ae3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-024-05761-y$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://doi.org/10.1007/s00432-024-05761-y$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,864,885,27923,27924,41119,41487,42188,42556,51318,51575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38801430$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mao, Xingjun</creatorcontrib><creatorcontrib>Huang, Wen</creatorcontrib><creatorcontrib>Xue, Qing</creatorcontrib><creatorcontrib>Zhang, Xiaolei</creatorcontrib><title>Prognostic impact and immunotherapeutic implications of NETosis-related prognostic model in clear cell renal cell carcinoma</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Background
The ramifications of necroptosis on the prognostication of clear cell renal cell carcinoma (ccRCC) remain inadequately expounded.
Methods
A prognostic model delineating the facets of necroptosis in ccRCC was constructed, employing a compendium of algorithms. External validation was effectuated using the E-MTAB-1980 dataset. The exploration of immune infiltration scores was undertaken through the exploitation of multiple algorithms. Single-cell RNA sequencing data were procured from the GSE171306 dataset. Real-time quantitative PCR (RT-qPCR) was engaged to scrutinize the differential expression of SLC25A37 across cancer and paracancer tissues, as well as diverse cell lines. Assessments of proliferative and metastatic alterations in 769-P and 786-O cells were accomplished through Cell Counting Kit-8 (CCK8) and wound healing assays.
Results
The necroptosis-related signature (NRS) emerges as a discerning metric, delineating patients’ immune attributes, tumor mutation burden, immunotherapy response, and drug susceptibility. Single-cell RNA sequencing analysis unveils the marked enrichment of SLC25A37 in tumor cells. Concurrently, RT-qPCR discloses the overexpression of SLC25A37 in both ccRCC tissues and cell lines. SLC25A37 knockdown mitigates the proliferative and metastatic propensities of 769-P and 786-O cells, as evidenced by CCK8 and wound healing assays.
Conclusion
The NRS assumes a pivotal role in ascertaining the prognosis, tumor mutation burden, immunotherapy response, drug susceptibility, and immune cell infiltration features of ccRCC patients. SLC25A37 emerges as a putative player in immunosuppressive microenvironments, thereby providing a prospective avenue for the design of innovative immunotherapeutic targets for ccRCC.</description><subject>Algorithms</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Cancer Research</subject><subject>Carcinoma, Renal Cell - genetics</subject><subject>Carcinoma, Renal Cell - immunology</subject><subject>Carcinoma, Renal Cell - pathology</subject><subject>Carcinoma, Renal Cell - therapy</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation</subject><subject>Clear cell-type renal cell carcinoma</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Immunotherapy - methods</subject><subject>Infiltration</subject><subject>Internal Medicine</subject><subject>Kidney cancer</subject><subject>Kidney Neoplasms - genetics</subject><subject>Kidney Neoplasms - immunology</subject><subject>Kidney Neoplasms - pathology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Microenvironments</subject><subject>Mutation</subject><subject>Necroptosis</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Sequence analysis</subject><subject>Tumor cells</subject><subject>Tumor Microenvironment - immunology</subject><subject>Tumors</subject><subject>Wound healing</subject><issn>1432-1335</issn><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kUtv1TAQhSNERUvhD7BAkdh0Exg_8lohVLWAVFEWd29NnMmtK8cOdlLpij-PL7n0waLeeOTzzRmPTpa9Y_CRAdSfIoAUvAAuCyjrihW7F9kJ2z8xIcqXj-rj7HWMtwCsLmv-KjsWTQNJhJPs98_gt87H2ejcjBPqOUfXp3JcnJ9vKOBEy0G0RuNsvIu5H_IfFxsfTSwCWZypz6cHn9H3ZHPjcm0JQ67J2jyQQ7uWGoM2zo_4Jjsa0EZ6e7hPs83lxeb8W3F1_fX7-ZerQouymotey0pgU9akh0Y0Neuw4cR5J3VFWtathK7FTsueNyVIYNWAUmDZs7bjSOI0-7zaTks3Uq_JzQGtmoIZMeyUR6OeKs7cqK2_U4wx3qaTHM4ODsH_WijOajRxvws68ktUAiqoZcslJPTDf-itX0LafaXKSjbQJIqvlA4-xkDD_W8YqH22as1WpWzV32zVLjW9f7zHfcu_MBMgViAmyW0pPMx-xvYPn7OzAA</recordid><startdate>20240527</startdate><enddate>20240527</enddate><creator>Mao, Xingjun</creator><creator>Huang, Wen</creator><creator>Xue, Qing</creator><creator>Zhang, Xiaolei</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240527</creationdate><title>Prognostic impact and immunotherapeutic implications of NETosis-related prognostic model in clear cell renal cell carcinoma</title><author>Mao, Xingjun ; Huang, Wen ; Xue, Qing ; Zhang, Xiaolei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-dc463a857ecf83871ba82e22b4c6ec47940b9abc4d28504016fa43a5d19b2ae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Algorithms</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Cancer Research</topic><topic>Carcinoma, Renal Cell - genetics</topic><topic>Carcinoma, Renal Cell - immunology</topic><topic>Carcinoma, Renal Cell - pathology</topic><topic>Carcinoma, Renal Cell - therapy</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation</topic><topic>Clear cell-type renal cell carcinoma</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Immunotherapy - methods</topic><topic>Infiltration</topic><topic>Internal Medicine</topic><topic>Kidney cancer</topic><topic>Kidney Neoplasms - genetics</topic><topic>Kidney Neoplasms - immunology</topic><topic>Kidney Neoplasms - pathology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Microenvironments</topic><topic>Mutation</topic><topic>Necroptosis</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Sequence analysis</topic><topic>Tumor cells</topic><topic>Tumor Microenvironment - immunology</topic><topic>Tumors</topic><topic>Wound healing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mao, Xingjun</creatorcontrib><creatorcontrib>Huang, Wen</creatorcontrib><creatorcontrib>Xue, Qing</creatorcontrib><creatorcontrib>Zhang, Xiaolei</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mao, Xingjun</au><au>Huang, Wen</au><au>Xue, Qing</au><au>Zhang, Xiaolei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic impact and immunotherapeutic implications of NETosis-related prognostic model in clear cell renal cell carcinoma</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2024-05-27</date><risdate>2024</risdate><volume>150</volume><issue>5</issue><spage>278</spage><epage>278</epage><pages>278-278</pages><artnum>278</artnum><issn>1432-1335</issn><issn>0171-5216</issn><eissn>1432-1335</eissn><abstract>Background
The ramifications of necroptosis on the prognostication of clear cell renal cell carcinoma (ccRCC) remain inadequately expounded.
Methods
A prognostic model delineating the facets of necroptosis in ccRCC was constructed, employing a compendium of algorithms. External validation was effectuated using the E-MTAB-1980 dataset. The exploration of immune infiltration scores was undertaken through the exploitation of multiple algorithms. Single-cell RNA sequencing data were procured from the GSE171306 dataset. Real-time quantitative PCR (RT-qPCR) was engaged to scrutinize the differential expression of SLC25A37 across cancer and paracancer tissues, as well as diverse cell lines. Assessments of proliferative and metastatic alterations in 769-P and 786-O cells were accomplished through Cell Counting Kit-8 (CCK8) and wound healing assays.
Results
The necroptosis-related signature (NRS) emerges as a discerning metric, delineating patients’ immune attributes, tumor mutation burden, immunotherapy response, and drug susceptibility. Single-cell RNA sequencing analysis unveils the marked enrichment of SLC25A37 in tumor cells. Concurrently, RT-qPCR discloses the overexpression of SLC25A37 in both ccRCC tissues and cell lines. SLC25A37 knockdown mitigates the proliferative and metastatic propensities of 769-P and 786-O cells, as evidenced by CCK8 and wound healing assays.
Conclusion
The NRS assumes a pivotal role in ascertaining the prognosis, tumor mutation burden, immunotherapy response, drug susceptibility, and immune cell infiltration features of ccRCC patients. SLC25A37 emerges as a putative player in immunosuppressive microenvironments, thereby providing a prospective avenue for the design of innovative immunotherapeutic targets for ccRCC.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>38801430</pmid><doi>10.1007/s00432-024-05761-y</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1432-1335 |
ispartof | Journal of cancer research and clinical oncology, 2024-05, Vol.150 (5), p.278-278, Article 278 |
issn | 1432-1335 0171-5216 1432-1335 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11129999 |
source | MEDLINE; DOAJ Directory of Open Access Journals; Springer Nature OA/Free Journals; SpringerLink Journals - AutoHoldings |
subjects | Algorithms Biomarkers, Tumor - genetics Cancer Research Carcinoma, Renal Cell - genetics Carcinoma, Renal Cell - immunology Carcinoma, Renal Cell - pathology Carcinoma, Renal Cell - therapy Cell Line, Tumor Cell Proliferation Clear cell-type renal cell carcinoma Gene Expression Regulation, Neoplastic Hematology Humans Immunotherapy Immunotherapy - methods Infiltration Internal Medicine Kidney cancer Kidney Neoplasms - genetics Kidney Neoplasms - immunology Kidney Neoplasms - pathology Medicine Medicine & Public Health Metastases Metastasis Microenvironments Mutation Necroptosis Oncology Prognosis Sequence analysis Tumor cells Tumor Microenvironment - immunology Tumors Wound healing |
title | Prognostic impact and immunotherapeutic implications of NETosis-related prognostic model in clear cell renal cell carcinoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T06%3A40%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20impact%20and%20immunotherapeutic%20implications%20of%20NETosis-related%20prognostic%20model%20in%20clear%20cell%20renal%20cell%20carcinoma&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Mao,%20Xingjun&rft.date=2024-05-27&rft.volume=150&rft.issue=5&rft.spage=278&rft.epage=278&rft.pages=278-278&rft.artnum=278&rft.issn=1432-1335&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-024-05761-y&rft_dat=%3Cproquest_pubme%3E3060564808%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3060564808&rft_id=info:pmid/38801430&rfr_iscdi=true |